Centessa Pharmaceuticals plc
CNTA
Rangering i aksjer
#2961
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical... Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.
Aksjekurs
$40.50
Sist synkronisert: 2026-06-29
Markedsverdi
$6.22B
Endring (1 dag)
0.00%
Endring (1 år)
77.71%
Land
GB
Handel Centessa Pharmaceuticals plc (CNTA)
Kategori
Healthcare
Antall utestående aksjer for Centessa Pharmaceuticals plc (CNTA)
Antall utestående aksjer per March 2026: 153.55M
Ifølge Centessa Pharmaceuticals plc sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 153.55M. Ved slutten av December 2023 hadde selskapet 96.18M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Centessa Pharmaceuticals plc (CNTA) fra 2019 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 153.55M | 34.14% |
| 2024 | 114.47M | 19.02% |
| 2023 | 96.18M | 2.97% |
| 2022 | 93.40M | 3.79% |
| 2021 | 89.99M | 26.94% |
| 2020 | 70.89M | -33.42% |
| 2019 | 106.47M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 65.35% |
US
|
|
| 396.00M | 157.90% |
US
|
|
| 478.91M | 211.89% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -59.50% |
NL
|
